Allergy Therapeutics PLC Annual Report and Accounts Delayed (0237X)
December 15 2023 - 6:48AM
UK Regulatory
TIDMAGY
RNS Number : 0237X
Allergy Therapeutics PLC
15 December 2023
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Publication of Annual Report and Accounts Delayed
Temporary Suspension of Shares
15 December 2023 Allergy Therapeutics plc (AIM: AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, announces that its auditor, BDO LLP ("BDO"), has informed
the Company that it requires additional time to complete its audit
for the year ended 30 June 2023, due to resource availability
within the audit engagement team.
As a result of the delay to the audit process, the Company will
not meet the deadline to publish its annual report and accounts by
31 December 2023. Consequently, the Company is not able to comply
with the requirements of AIM Rule 19 of the AIM Rules for Companies
which requires publication of the Company's annual report and
accounts within six months of the year end. Accordingly, the
Company's ordinary shares will be suspended from trading on AIM
with effect from 7.30 a.m. on 2 January 2024.
The Company's ordinary shares will remain temporarily suspended
from trading on AIM until such time as the Company has satisfied
the requirements of AIM Rule 19 with respect to publication of its
annual report and accounts. The final audit and subsequent
publication of Allergy Therapeutics' annual report and accounts are
aiming to be completed as soon as possible, this is anticipated to
occur by the end of January 2024.
For further information on the Company, please visit the
website: www.allergytherapeutics.com .
This announcement contains inside information for the purposes
of the UK Market Abuse Regulations.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
ICR Consilium
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company, headquartered in the UK, focussed on the
treatment and diagnosis of allergic disorders, including aluminium
free immunotherapy vaccines that have the potential to cure
disease. The Group sells proprietary and third-party products from
its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad
pipeline of products in clinical development includes vaccines for
grass, tree, house dust mite and peanut. For more information,
please see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSFLFSFFRLELIV
(END) Dow Jones Newswires
December 15, 2023 07:48 ET (12:48 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024